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ABSTRACT
Motivation: Large-scale genetic association studies are carried
out with the hope of discovering single nucleotide polymorphisms
involved in the etiology of complex diseases. There are several
existing methods in the literature for performing this kind of analysis
for case-control studies, but less work has been done for prospective
cohort studies. We present a Bayesian method for linking markers
to censored survival outcome by clustering haplotypes using gene
trees. Coalescent-based approaches are promising for LD mapping,
as the coalescent offers a good approximation to the evolutionary
history of mutations.
Results: We compare the performance of the proposed method in
simulation studies to the univariate Cox regression and to dimension
reduction methods, and we observe that it performs similarly in
localizing the causal site, while offering a clear advantage in terms
of false positive associations. Moreover, it offers computational
advantages. Applying our method to a real prospective study, we
observe potential association between candidate ABC transporter
genes and epilepsy treatment outcomes.
Availability: R codes are available upon request.
Contact: ioanna.tachmazidou@imperial.ac.uk
Supplementary information: Supplementary data are available at
Bioinformatics online.
1 INTRODUCTION
Much of the current focus in human genetics is on disentangling
the genetic contribution to complex diseases via genetic association
studies. Numerous methods have been proposed for the analysis of
genetic data from case-control studies, but very little is available
for the analysis of time-to-event outcomes, such as patients’overall
survival time or time to cancer recurrence.
The most popular approach to modelling survival data is the Cox
proportional-hazards regression (Cox, 1972). However, in the
contextofgeneticassociationstudies,Coxregressionfacesthesame
problems as common regression which are related mainly to the
size of datasets currently being collected and the collinearity
between markers that may exist due to linkage disequilibrium (LD).
∗To whom correspondence should be addressed.
The simplest approach would be to use univariate Cox models to
assess the association between each marker and outcome separately.
However, univariate analyses can be inefﬁcient as they do not
account for the aforementioned statistical correlation or LD between
markers, as opposed to multi-marker approaches.
In this article, we propose to tackle these problems (high-
dimensionality and multi-collinearity) by clustering haplotypes with
similar hazard risks. The proposed method is an extension of
approach described in Tachmazidou et al. (2007), which deals with
case-control data. Here, we assume a parametric model for survival
times and search for genetic variants, mostly single nucleotide
polymorphisms (SNPs), that show important associations with the
survival times. In particular, we scan the chromosomal region of
interest for sub-regions of no obligate recombination, or parallel
and back mutations. Each sub-region can be represented by a
unique evolutionary tree, called gene tree or perfect phylogeny
(PP) (Grifﬁths, 2001), whose topology approximates the mutational
history of the haplotypes therein. Coalescent approaches are
promising for LD mapping, as the coalescent is likely to provide
a better approximation to the evolutionary history of mutations
compared to empirical clustering methods. We use a Markov
chain Monte Carlo (MCMC) algorithm to iteratively sample from
the PPs that make up our genetic region, and we cluster the
haplotypes according to the relative ages of the markers in the
sampled PP. The main idea behind our clustering metric is that
ancestrally similar haplotypes are likely to have similar hazard
risks. After convergence, we obtain the posterior probability of
each SNP being a cluster centre, and we treat this as the posterior
density of the location of a putative causal variant, since high
values correspond to markers where haplotypes are best separated,
suggesting the presence in the region of a variant inﬂuencing
the risk of the clinical event. The proposed method is fast and
can handle large datasets with many markers and/or patients. Its
performance is compared in simulation studies to the univariate
Cox regression, and to the dimension reduction methods of Li
and Gui (2004), implemented in the software PCRCox, and Bair
and Tibshirani (2004) and Bair et al. (2006), implemented in the
software SUPERPC.
Li and Gui (2004) propose a partial Cox regression (PCR) method
that constructs uncorrelated components via repeated least square
ﬁtting of residuals and Cox regression ﬁtting. From the resulting
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PCR components, the ﬁrst k most important are determined by
univariate Cox regression. Li and Gui (2004) also suggest that
using PC analysis to ﬁnd the non-trivial principle components
and then ﬁtting only these using their method, results in a more
parsimonious model.
Bair and Tibshirani (2004); Bair et al. (2006) propose
a semi-supervised form of PC analysis, called Supervised
Principle Components (SPC). SPC initially computes univariate
Cox regression coefﬁcients, and retains those variables whose
coefﬁcients exceed in absolute value some threshold, estimated by
cross-validation. Using the reduced dataset, it computes the ﬁrst few
principle components and provides important scores for the initial
variables.
In our simulation studies, we consider different scenarios
varying in genetic relative risk, minor allele frequency of the
causal allele, sample size and censoring. The proposed method
yields similar localization performance to the other methods
considered, while showing a clear advantage in terms of false
positive associations. We applied our approach to data from the
SANAD (a study of Standard and New Antiepileptic Drugs) UK
prospective study (www.liv.ac.uk/neuroscience/sanad) and found
potential associations between candidate ATP-binding cassette
(ABC) transporter genes and epilepsy treatment outcomes.
2 METHODS
2.1 Perfect phylogenies
Over genomic regions characterized by strong LD, where there is no
evidence of recombination and recurrent point mutations, haplotypes are
said to have evolved according to a PP. Haplotypes within these regions
can be represented by a unique gene tree that describes their mutational
history.
For example, Table 1 represents the incidence matrix for a set of 4000
haplotypes. Columns correspond to six diallelic SNPs and rows are the
unique haplotypes in the dataset. Alleles are coded as 0 for the major allele
and 1 for the minor allele.Arooted PP assumption poses the constraint that,
for any two SNPs in the incidence matrix, not all three combinations (01,
10, 11) exist. In contrast, recombination and back or parallel mutation lead
to the possible existence of all three combinations.
When the PP assumption is valid, we can use Gusﬁeld’s algorithm
(Gusﬁeld, 1991) to construct the gene tree compatible with the data. Figure 1
shows the gene tree for the haplotypes in Table 1. The nodes in the tree
correspond to mutations and the gene tree is rooted at the haplotype with all
major alleles. Mutations are ordered on the tree according to their relative
age. If the causal mutation is embedded between SNPs 2 and 3 say, all
descendant haplotypes will inherit it and will therefore have a more recent
shared ancestry than the other haplotypes. Thus, the survival associated with
the 567 haplotypes that correspond to the last two branches of the tree
will tend to be similar. However, the phenotype–haplotype relationship may
becomemorefuzzyduetodominance,epistasisortheeffectofenvironmental
factors.
Therefore, the use of the PP model implies little or no recombination in
genomicsegmentsandthe‘inﬁnitelymanysites’assumptionfrompopulation
genetics. We propose to split the chromosomal region of interest into
consecutive PPs with window boundaries deterministically deﬁned by the
locationswherethePPassumptionbreaks.Detailsofhowthisisimplemented
are given in Tachmazidou et al. (2007). Once the set of windows and
corresponding trees have been identiﬁed, we use a Bayesian partition model
to search through trees to identify those, if any, where the corresponding set
of haplotypes appear to form clusters that discriminate high from low-hazard
risk, thus possibly harbouring a causal variant.
Table 1. Incidence matrix for six distinct haplotypes and their frequencies,
consisting of six SNPs (S1–S6)
Frequency S1 S2 S3 S4 S5 S6
2 0 4 110000
9 3 2 110011
2 3 3 110010
2064 000000
5 6 5 011100
2 011000
Fig. 1. The gene tree consistent with the haplotypes in Table 1. Labels
1–6 refer to mutations S1–S6. At the bottom of each branch, we report the
multiplicity of each observed haplotype in the sample.
2.2 Haplotype clustering
WeuseaBayesianpartitionmodeltosplitthehaplotypespaceintoanapriori
unknown number of disjoint clusters on the basis of haplotype similarity.
Our similarity measure has an evolutionary interpretation, with sequences
sharing a cluster depending on the time to their most recent common
mutation. In other words, our distance metric is based on the order with
which the mutations have arisen in the haplotype sample. This information
is provided by the topology of the gene tree. Therefore, any SNPset selected
as cluster centres can be time ordered and we assign haplotypes to clusters
according to the relative ages of these centres.
Suppose, for example that SNPs 1, 3 and 5 of Figure 1 are selected as
cluster centres. SNP 5 is younger than SNP 1, and SNP 3 is on a different
branch, implying that a haplotype carrying mutation 3 cannot carry mutation
1 or 5. Starting with SNP 5, we assign the haplotypes that correspond to
the third and fourth branch of the tree as members of this cluster. Only the
second haplotype is assigned to the cluster with SNP 1 as centre because,
although the third and fourth haplotypes carry mutation 1, they have been
already allocated to a cluster. The last two haplotypes are allocated to a
separate cluster with centre SNP 3, and the remaining haplotype is assigned
to a hypothetical ‘null’ cluster, which can be interpreted as a baseline risk
group.Therefore,everyhaplotypeisdeterministicallyallocatedtothecluster
with the closest centre. Haplotypes within each cluster are assumed to have
similar survival probabilities and risks.
2.3 Modelling approach
Letusassumethatthehaplotypedatacanbesplitintontr PPorgenetrees,that
tree T is selected as harbouring the causal mutation and that the haplotype
space is currently partitioned into nc=nclust+1 clusters (nc includes the
‘null’cluster, while nclust is the number of SNPs selected as cluster centres).
Conditionally on tree T, an indicator vector γ represents the partition, with
γ =(γ1,...,γnSNPT ), γk ∈(0,1), k=1,...,nSNPT, such that γk =1i ft h ek-th
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SNP is selected as cluster centre and γk =0 otherwise, where nSNPT is the
number of SNPs in T.
For a failure time X, right-censored data can be represented by pairs
of random variables (t,δ). When the lifetime X is observed, δ=1 and t is
equaltoX,whilstforright-censoreddata,δ=0andt isequaltothecensoring
time Cr, i.e. t=min(X,Cr). Therefore, δij∈{0,1} is the censoring status
indicator of survival time tij for haplotype i=1,...,nj in cluster j=
1,...,nc. The vector of responses for cluster j is denoted by Dj=
{(t1j,δ1j),...,(tnjj,δnjj)}  and let D={Dj,j=1,...,nc}. Each tij is assumed
to have an exponential distribution with cluster-speciﬁc parameter θj. Thus,
the likelihood of the data is:
L =
nc 
j=1
θ
nj
i=1δij
j exp

−θj
nj 
i=1
tij

,
where
nj
i=1tij is the total time in the study for all nj haplotypes in cluster j,
and
nj
i=1δij is the observed number of events (e.g. deaths) in cluster j, with
j=1,...,nc. Parameters θj are given independent Gamma(ν0,ν1) priors. The
marginal probability of the data is available analytically and given by
p(D|γ,ν0,ν1) =

ν
ν0
1
 (ν0)
nc nc 
j=1
 

ν0+
nj
i=1δij
	
(ν1+
nj
i=1tij)ν0+
nj
i=1δij
(1)
where   denotes the Gamma function.
A priori each tree is equally likely to contain the putative mutation.
Conditionally on tree T, we impose a binomial prior on the number of cluster
centres nclust. Given nclust, any cluster conﬁguration is equally likely a priori.
Then the joint prior distribution of tree T and partition γ is given by
p(T,γ) = p(T)p(γ|T)=p(T)p(nclust|T)p(γ|nclust,T)
=
1
ntr

nSNPT
nclust

qnclust(1−q)nSNPT −nclust 1 
nSNPT
nclust
, (2)
where q is the success probability of the Binomial distribution, and can be
chosen to penalize or favour big number of clusters in such a way to reﬂect
the investigator’s prior beliefs.
The posterior conditional distribution of θj is also available in closed form
θj|Dj,γ,ν0,ν1 ∼ Gamma

ν0+
nj 
i=1
δij,ν1+
nj 
i=1
tij

,∀j=1,...,nc.
Upon convergence, we obtain a posterior sample of partitions and an
estimate of the posterior probability that the causal mutation is embedded
within each of the trees. We then calculate the Bayes factor in favour of
association at each marker site as the ratio of the posterior to prior odds
(Kass and Raftery, 1995), where the prior odds of each SNP being a cluster
centre is evaluated by simulation using Equation (2).
2.4 Details of the MCMC algorithm
We use an MCMC algorithm to sample from the posterior distribution over
the space of possible partitions. At each MCMC iteration, we perform two
M-H steps:
• Change partition: sample a new partition from the posterior
distribution of the cluster centres without changing the current
gene tree.
• Update tree: sample a new tree and a new partition from their joint
posterior distribution.
In particular, we use a Metropolis–Hastings (M–H) step to sample from
the conditional distribution of partition γ given the data and tree T.W e
consider two possible moves in the partition space: adding (birth) or deleting
(death) a cluster centre. At each move, we randomly select SNP i and
we propose γ  
i =1, if the current γi=0o rγ  
i =0 otherwise. Thus, the
proposal distribution q(γ  |γ) is simply 1/nSNPT. Given the cluster centres,
the observed haplotypes are deterministically allocated to the haplotype
clusters according to our similarity metric. The logarithm of the acceptance
probability for the ﬁrst M-H sampler (a1) simpliﬁes to the logarithm of
the Bayes factor (BF) in favour of γ   over γ, i.e. p(D|γ  )/p(D|γ) where
the marginal probability is calculated using Equation (1) ± log((1−q)/q)
depending if the death or birth of a cluster centre is proposed respectively,
i.e.
log(a1)=log


BF(γ  ,γ)

±log

1−q
q

=log

p(D|γ  )
p(D|γ)

±log

1−q
q

.
We use a second M-H step to sample a tree from the ntr possible trees with
probability1/ntr andanewpartitiongiventhetree.EachSNPinthetreehasa
0.5 probability of being proposed as a cluster centre. Therefore, the proposal
probability of the tree and the partition space is equal to 1/(ntr×2nSNPT ),
and the joint prior distribution of a gene tree T and a partition γ is given
by Equation (2). The logarithm of the acceptance probability for the second
M-H sampler (a2) simpliﬁes to the logarithm of the Bayes factor in favour
of the proposed partition over the current partition plus the logarithm of the
prior ratio and the logarithm of the proposal ratio, i.e.
log(a2)=log


BF(γ  ,γ)

+K=log

p(D|γ  )
p(D|γ)

+K,with
K=(n
prop
SNPT −ncurr
SNPT)log(2)+(n
prop
clust−ncurr
clust)log(q)+(n
prop
SNPT −n
prop
clust−ncurr
SNPT
+ncurr
clust)log(1−q), where n
prop
SNPT and ncurr
SNPT is the number of SNPs in the
proposed and current tree respectively, and n
prop
clust and ncurr
clust is the number of
clusters in the proposed and current tree, respectively.
3 RESULTS
3.1 Simulation study
The performance of the proposed method was compared to that of
theunivariateCoxregression,thePCRCoxandSUPERPCsoftware.
PCRCox and SUPERPC were mainly developed for analysing gene
expressiondata.Here,weexploretheirperformancewhensearching
for marker-survival phenotype associations.
We simulated a population of 20000 haplotypes over 1
Mb chromosomal region with recombination hotspots using the
FREGENE software (Hoggart et al., 2007) under the default
parameters. From the simulated data, we retained markers with
minor allele frequency (MAF) ≥1%. From these markers, we
selected 1000 SNPs with probability proportional to p(1−p), where
p is the allele frequency of a marker in the sample. In this way, we
obtain an average spacing of 1kb. We then selected at random a
SNP with allele frequency between p−0.005 and p+0.005, where
p was in a range between 0.02 and 0.3, to be the causal locus.
We sampled with replacement pairs of haplotypes to form an
individual’s genotype and generated their survival times from
a Gompertz(α,β) distribution (with α=1,β=1). The Gompertz
distribution (Gompertz, 1825) is a popular probability model for
human mortality and it is a proportional hazards model like the Cox
model.
Assuming additive genotype effect, the hazard function is given
by h(t|Gi)=βeαteρGi, where Gi is the number of copies of the
causal allele, Gi=0,1,2, and ρ is the logarithm of the hazard
relative risk of the heterozygote, HRR(Aa). We varied the relative
risk between 1.2 and 3. The censoring times were generated
from an exponential distribution with mean equal to t =1/λ.
To evaluate t , we assumed that 5% of the whole population
experiences the disease by time t , i.e. P(t≤t )=P(t≤t |G0)
(1−p)2+P(t≤t |G1)2p(1−p)+P(t≤t |G2)p2=5%,whereP(t≤
t ) is the cumulative distribution function of the survival times,
and p is the allele frequency of the causal variant. We considered
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a censoring level of 30, 50, 70 and 90%, and sample sizes of 400,
1000, 2000 and 4000 individuals, which at the 90% censoring level
yielded 40, 100, 200 and 400 disease cases, respectively.
In all analyses, we removed the causal allele from the dataset and,
using the technique described in the ‘Perfect phylogenies’ section,
we constructed the perfect phylogenies in the dataset. The average
number of gene trees was 200 and the average number of SNPs in
a gene tree was 4.
The MCMC algorithm was run for 100000 iterations with
a burn-in of 10000 iterations for 50 datasets under different
combinations of the simulation parameters. For a dataset of 1000
markers and 4000 haplotypes the proposed method took 14 min
to construct the phylogenies and 13 min to run the algorithm
on an Intel Xeon 3.40GHz processor with 2Gb of memory.
The computing time for PCRCox and SUPERPC was 4 and 59
min respectively. An R (www.r-project.org) package called BETA-
Surv (Bayesian Evolutionary Tree-based Association analysis for
Survival) implementing the proposed method is available on request
from the ﬁrst author.
In the simulated and real data examples, we set the prior
hyperparameters as follows: we assume a Gamma(0.1,0.1) prior
on θj, j=1,...,nc, and a Binomial(nSNPT,p=0.98) for nclust given
tree T. Such a high success probability of the Binomial reﬂects an
a priori belief that each haplotype in the tree has its own risk.
3.2 Model performance
We investigate the performance of BETA-Surv, univariate Cox,
PCRCox and SUPERPC in terms of localization, power and false
positive rates. To run PCRCox, we ﬁrst performed PC analysis and
we only used the signiﬁcant principle components (i.e. those whose
SD is bigger than 10−10 in absolute value), as suggested in the
software documentation. We were also advised (Jiang Gui, personal
communication)thattheﬁrstﬁveprinciplecomponentswereusually
sufﬁcient. From these, we estimated regression coefﬁcients of the
original variables. SUPERPC returns importance scores for each of
the signiﬁcant variables, which we use to estimate associations. In
order to estimate the best threshold, SUPERPC computes a cross-
validated likelihood ratio (LR) statistic using the ﬁrst, the ﬁrst two
or the ﬁrst three principle components. Because for most of the
simulated datasets none of the three LR tests were signiﬁcant, we
calculated scores using three different thresholds (i.e. using the
ﬁrst, the ﬁrst two or the ﬁrst three principle components), and
we took the mean value of the scores for each signiﬁcant SNP.
Results reported for each simulation scenario are averages over 50
replicates. However, SUPERPC spuriously failed to produce results
onapproximatelyhalfofthedatasetsundereachscenario.Therefore,
for this method results are over approximately 25 replicates.
To measure each method’s accuracy in estimating the position of
an untyped causal allele, we report the probability that the identiﬁed
location is within some distance from the true location. The position
of the susceptibility variant is estimated by the physical location of
the SNP with the maximum Bayes factor for the proposed approach
and with the minimum P-value for univariate Cox regression.
For PCRCox and SUPERPC the causal location is estimated by
the SNP with the highest absolute regression coefﬁcient or score,
respectively.
To determine power, we deﬁne a window of 100 kb either side of
the causative allele and calculate the proportion of the 50 replicates
having a signiﬁcant association within the window.The signiﬁcance
of a signal is assessed via the following rules. For BETA-Surv, a
SNP is considered to have positive signal when its Bayes factor in
favour of association is ≤3 (Kass and Raftery, 1995). For univariate
Cox regression, we use two different signiﬁcance thresholds, i.e. a
P-value ≤0.05, and the Bonferroni-adjusted value. For PCRCox
and SUPERPC, a SNP is regarded as a positive hit if its regression
coefﬁcient or score, in absolute value, is larger than or equal to
the upper 90% quantile of the absolute value of the regression
coefﬁcients or scores, respectively. We also deﬁne as false positives
thosemarkerswithsmallerP-values,largerBayesfactors,orsmaller
absolute regression coefﬁcients or scores lying outside a window of
100kb either side of the causal variant.
3.3 Results across a range of simulation scenarios
Figure 2 shows the localization performance of the different
methods. Results are averages over 50 simulated datasets under
a default scenario, with 2000 sample size, 1.6 HRR(Aa), MAF
of causal allele 5% and 50% censoring. Overall, BETA-Surv and
univariate Cox perform better than PCRCox and SUPERPC. For
BETA-SurvandunivariateCox,therewerenosigniﬁcantdifferences
in the distribution of distances for reasonable location errors, with
univariate Cox showing advantage for distances >100kb.
Figure 3 reports the power and false positive rates of the methods
for the 50 datasets simulated under the default scenario. Univariate
CoxandPCRCoxhavethehighestpower,buttheworstperformance
in false positives. BETA-Surv and SUPERPC have similar power,
but BETA-Surv has the lowest false positive rate, which is almost
as low as Bonferroni-corrected univariate Cox.
In Supplementary Figure 1, we plot the power and false positive
ratesofthedifferentmethodsacrossthevarioussimulationscenarios
and over the 50 replicates. In each plot, we vary a simulation
parameter along the x-axis whilst assuming default values for the
remaining ones. Uncorrected single locus test and PCRCox are the
most powerful approaches, having however the worst performance
intermsoffalsepositives.ThefalsepositiveratesforBETA-Survare
verylowunderallsimulationscenarios.Thesameconclusionsapply
when we vary the censoring level. The choice of a 100 kb window
is sensible but arbitrary; a 200 kb window was also investigated and
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did not alter conclusions about both power or false positives. Also,
usingtheupper95%quantileoftheabsolutestandardizedregression
coefﬁcients or scores for PCRCox and SUPERPC, instead of the
90%, results in lower power and lower false positive rates for these
methods, but BETA-Surv has still by far the best performance in
terms of false positives.
To show the trade-off between power and false positive rate
for the different methods using varying signiﬁcance thresholds,
we plot ROC curves for the different simulation scenarios (Fig. 4
and Supplementary Figs 2–5). The threshold for univariate Cox
regression ranges between Bonferroni correction and 0.05, for
BETA-Surv from 1.1 to 10, and for PCRCox and SUPERPC from
60% to 100%.The graphs show that BETA-Surv and univariate Cox
regression are the best performing methods. Compared to univariate
Cox regression, BETA-Surv has a small advantage in power when
the association signal is weak, while it performs similarly for
stronger signals. However, it has lower false positive rate in every
simulation scenario. Overall, SUPERPC has the worst performance
in power, whereas PCRCox has the worst performance in false
positive associations.
Finally, we constructed 50 datasets under a null model of no
disease association and we calculated the false positive rate. For
the univariate analysis, this was 5.39% (P-value≤0.05) and 0
when using Bonferroni correction, while BETA-Surv resulted in
a false positive rate of 0.634% (Bayes factor≥3). PCRCox and
SUPERPC had a 10% and 4.80% false positive rate using the
upper 90% quantile, and 5% and 2.46% using the upper 95%
quantile, respectively.
3.4 Prospective epilepsy study
The ABC proteins are a superfamily of efﬂux pumps that extract
several classes of drugs from the eukaryotic cell. The ABC
transporters are currently the focus of a major effort to determine
their role in mediating drug resistance in a variety of human diseases
including cancer (Ambudkar et al., 2003), HIV (Sankatsing et al.,
2004) and epilepsy (Schmidt and Loscher, 2005).
Retrospectivestudieshavereportedassociationsbetweenepilepsy
treatment outcome and drug transporter genes (Siddiqui et al.,
2003; Zimprich et al., 2004), using individual SNPs or 3-SNP
haplotypes. However, results have been contradictory (Sills et al.,
2005; Tan et al., 2004). Leschziner et al. (2006b) analyzed data
from the UK SANAD prospective study for the gene complex
ABCB1/ABCB4. They used single SNP log-rank tests, 3-SNP
haplotype analyses and Cox multiple regression with stepwise
selection on a subset of the genotypes (due to the problems of
SNP collinearity and over-ﬁtting), and observed no signiﬁcant
genetic association.
Here, we use our proposed method to simultaneously analyze
ﬁve drug transporters genes. For a prospective cohort of 503
epilepsy patients from the SANAD study, 500 potential SNPs were
genotyped across ﬁve ABC transporter genes (ABCB1/ABCB4,
ABCC1, ABCC2 and ABCC5 located in 7q21.12, 16p13.1, 10q24
and 3q27 respectively). Details of genotyping, SNP identiﬁcation
and LD structure are given in Leschziner et al. (2006a). Of the
500 loci identiﬁed, only 317 were polymorphic with ∼60% of
SNPs with MAF ≥5%. SNPs with ≤1% MAF, showing evidence
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Fig. 5. Results for geneABCC1 from BETA-Surv and univariate Cox regression for the SANAD epilepsy cohort with outcome ‘time to 12 month remission’.
Bayes factor in favour of association at each marker from BETA-Surv (A), and P-values from Cox regression (B) averaged over the 10 datasets.
Table 2. Summary of ABC genotype SANAD data
Gene size (kb) SNPs Mono MAF<1% HWD Miss>10% Used
ABCB1/4 283 186 73 22 3 5 85
ABCC1 193 162 50 12 5 3 92
ABCC2 69 76 32 19 2 3 24
ABCC5 98 76 28 8 4 2 34
Total 643 500 183 61 14 13 235
of Hardy Weinberg disequilibrium (HWD χ2
1 ≥ 12) or with ≥10%
missing per SNP were discarded, leaving a total of 235 SNPs for
analysis (Table 2).Treatment outcomes were prospectively recorded
for patients commencing anti-epileptic drug therapy. Here we
concentrate on two outcomes: time to 12 month remission (512
observed and 494 censored events), and time to withdrawal from
drug due to unacceptable adverse side-effects (194 observed and
812 censored events).
We used PHASE (Stephens et al., 2001) to phase the genotypes.
Each haplotype pair was chosen at random according to its posterior
probability. To account for phase uncertainty, we repeated the
above procedure 10 times and we analyzed each of the 10 datasets
separately. Gene region ABCB1/ABCB4 consists of 54 trees, and
genes ABCC1, ABCC2 and ABCC5 of 67, 14 and 27 trees,
respectively averaged over the 10 datasets.
For time to 12 month remission, the proposed method yielded no
evidence of association for ABCB1/ABCB4 and ABCC5 regions
for any of the datasets. For gene ABCC1, markerwise Bayes
factors from BETA-Surv and (−log)P-values from univariate Cox
regression, averaged over the 10 datasets, are given in Figure 5.
Positive hits from BETA-Surv were observed at 7495.248, 7497.311
and 7536.426 kb with average Bayes factors 3.68, 7.09 and 8.84,
respectively.ForgeneABCC2,bothBETA-SurvandCoxregression
identiﬁed the variant at position 20312.532 kb (average Bayes factor
4.08 and P-value 0.03).
For time to withdrawal due to adverse side-effects, the proposed
method yielded no evidence of association forABCB1/ABCB4 and
ABCC2 regions for any of the datasets. For gene ABCC1, BETA-
Surv found positive association at 7548.444kb with average Bayes
factor3.36,whereasCoxregressionreportedtheSNPat7549.729kb
with average P-value 0.026. For geneABCC5, both BETA-Surv and
Cox regression identiﬁed the variant at position 90194.67 kb in all
10 datasets (average Bayes factor 5.1 and P-value 0.03).
Generally,BETA-SurvandCoxregressionyieldedsimilarresults.
There is positive but not strong evidence of association between
some ABC transporter genes and epilepsy treatment outcomes. To
the best of our knowledge, there are no other reported analyses
or associations between genes ABCC1, ABCC2 or ABCC5 and
epilepsy.
4 DISCUSSION
We have presented a method to analyze genetic association studies
with time-to-event outcomes. Cohort studies are a useful and
increasingly common study design, but there is a noticeable lack
of statistical methods for their analysis. The method presented
here is best suited for densely genotyped candidate gene regions
and can easily handle large number of individuals and markers.
ComparedtounivariateCoxregressionandmulti-markerdimension
reduction techniques, our method performs similarly in terms
of localization, while offering clear advantages in terms of
false positive associations. Moreover, it runs fast and it offers
computational advantages especially over methods that rely on
cross-validation to determine model parameters.
Here, we assume that survival times can be modelled
parametrically by the exponential distribution within each cluster.
Theuseofsuchasimpledistributionmayseemrestrictive,butoffers
computational advantages over more complicated models. We have
also used the Weibull distribution to model the survival outcome,
which in simulation studies offered no signiﬁcant additional
advantages, while increasing the running times of the method.
The incorporation of environmental covariates in the model is an
issue that has not been investigated in this work. One possible way
ofdealingwiththis,isbyﬁttingacluster-speciﬁcsurvivalregression
using the exponential distribution.
Finally, phase uncertainty in haplotype reconstruction from
genotype data could be incorporated in the analysis by adding
another step in the MCMC algorithm and sampling from the
2035I.Tachmazidou et al.
different haplotype reconstructions at each MCMC step before
performing the rest of the analysis for the chosen phase. However,
this approach is likely to add signiﬁcant computational burden.
A simpler approach, and one we adopt in the application to the
real data, consists in repeating the analysis for a number of different
haplotype reconstructions and average the results.
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